Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38663623 | 1.00 | GBA1 (0.62) | GBA1CHRNB2CHRNA4CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL18280120 | 0.98 | GBA1 (0.61) | GBA1CHRNB2CHRNA4CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL3301662 | 0.98 | GBA1 (0.61) | GBA1CHRNB2CHRNA4CHRM2CHRM1 | |
| SCHEMBL2570698 | 0.90 | CHRNB2 (0.68) | GBA1CHRNB2CHRNA4CHRM2CHRM1 | |
| SCHEMBL18714677 | 0.90 | CHRNB2 (0.68) | GBA1CHRNB2CHRNA4CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL5250017 | 0.89 | CHRNB2 (0.66) | GBA1CHRNB2CHRNA4CHRM2CHRM1 | |
| SCHEMBL24933229 | 0.87 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| SCHEMBL31054426 | 0.84 | CHRNA7 (0.53) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| SCHEMBL9534698 | 0.84 | CHRNA7 (0.53) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 | |
| SCHEMBL27686945 | 0.84 | KDM4E (0.56) | CHRNB2CHRNA4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| EP-3724178-B1 | 1-(PIPERIDINOCARBONYLMETHYL)-2-OXOPIPERAZINE DERIVATIVES FOR TREATING CANCER | Inthera Bioscience AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-02 | — | — | US | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | SOUTHERN RESEARCH INSTITUTE (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | THE SCRIPPS RESEARCH INSTITUTE | 2022-06-30 | — | — | US | disclosed |
| US-11306068-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2022-04-19 | — | — | US | disclosed |
| WO-2009064835-A1 | 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009056693-A1 | NOVEL DERIVATIVES OF N, N'- 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS MEDICAMENTS PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008099073-A1 | N, N' -2, 4-DIANILINOPYRIMIDINES PREPARATION AND USE THEREOF AS IKK INHIBITORS PREPARATION AND TEH PHARMACUETICAL COMPOSITIONS THEREOF | SANOFI-AVENTIS (FR) | 2008-08-21 | — | — | WO | disclosed |
| US-5925635-A | 2-(OXO-1,3-PERHYDRODIAZEPINES OR 3-OXO-2,3,4,5-TETRAHYDRO-1H-2,4-BENZODIAZEPINES; ANTICOAGULANTS; ENZYME INHIBITORS OF SERINE PROTEASE THROMBIN, KALLIKREIN AND PLASMIN; NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-07-20 | — | — | US | disclosed |
| US-5719166-A | TREATING PSYCHOSES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1998-02-17 | — | — | US | disclosed |
| EP-0532177-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| US-5550136-A | ANTAGONISTS OF DOPAMINE D-2 RECEPTORS | ZENECA LIMITED (GB) | 1996-08-27 | — | — | US | disclosed |
| US-5399568-A | Dopamine antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-03-21 | — | — | US | disclosed |
| EP-0532177-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | GBA1 1097/4885CHRNB2 2666/4885CHRNA4 2001/4885 |
| US-11306068-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | GBA1 1097/4885CHRNB2 2666/4885CHRNA4 2001/4885 |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | GBA1 1097/4885CHRNB2 2666/4885CHRNA4 2001/4885 |
| US-20220204485-A1 | STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS | TTR, MAP1LC3B, SAAL1 | GBA1 546/4885CHRNB2 3387/4885CHRNA4 4246/4885 |
| US-11578073-B2 | Xanthine analogs as potent anti-West Nile viral agents | XDH, PNP, MAVS | GBA1 707/4885CHRNB2 2733/4885CHRNA4 1743/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | GBA1 1097/4885CHRNB2 2666/4885CHRNA4 2001/4885 |
| US-11945806-B2 | Stabilization of amyloidogenic immunoglobulin light chains | TTR, MAP1LC3B, SAAL1 | GBA1 546/4885CHRNB2 3387/4885CHRNA4 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.